Nebenwirkungen · Constella
Constella 290 micrograms hard capsules · Abschnitt 4.8 · PDF-Seite 4
HOS-215722 · Präparat HOS-155512
Summary of the safety profile Linaclotide has been given orally to 1 166 patients with IBS-C in controlled clinical studies. Of these patients, 892 patients received linaclotide at the recommended dose of 290 micrograms per day. Total exposure in the clinical development plan exceeded 1 500 patient-years. The most frequently reported adverse reaction associated with Constella therapy was diarrhoea, mainly mild to moderate in intensity, occurring in less than 20% of patients. In rare and more severe cases, this may – as a consequence – lead to the occurrence of dehydration, hypokalaemia, blood bicarbonate decrease, dizziness, and orthostatic hypotension.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T17:28:00Z · SHA-256 1b8acfd844e9f1cdcf705e8a60fee70d0baef38df36c3dc76756a130a5ec50d8 · Passage 285945cfb727bc00b75981bde7e5e4736d759c638afa87de17fba11070388794 · Zeichen 0–661 im Abschnitt